芪丹汤基于肥大细胞TNF-α调控腹膜间皮细胞NLRP3/IL-1β抗腹膜纤维化的机制研究
批准号:
82104750
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
王旭方
依托单位:
学科分类:
中医内科学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
王旭方
中文摘要
腹膜纤维化(PF)是腹透患者超滤衰竭的主要原因。肥大细胞参与PF,但机制不明。脂多糖(LPS)可使肥大细胞活化,后者释放的肿瘤坏死因子-α(TNF-α)等可激活腹膜间皮细胞(PMCs)NLRP3/IL-1β,介导炎症和转分化。预实验表明,以补气活血为主要治法的芪丹汤(黄芪、丹参)可抑制PMCs转分化。我们提出芪丹汤基于肥大细胞TNF-α调控PMCs NLRP3/IL-1β干预腹膜纤维化这一假说。本研究拟建立肥大细胞与PMCs共培养体系,观察LPS激活的肥大细胞TNF-α释放,及后者对PMCs NLRP3/IL-1β及转分化指标的影响。同时,构建腹透小鼠模型,观察芪丹汤、TNF-α抑制剂及肥大细胞稳定剂作用下PMCs NLRP3/IL-1β及转分化指标。本研究旨在探讨肥大细胞在PF中的作用,研究芪丹汤干预PF的机制,为中药治疗PF提供新的靶点,完善补气活血的中医治法理论在PF中的应用。
英文摘要
Peritoneal fibrosis (PF) is the leading cause of ultrafiltration failure and discontinuation of peritoneal dialysis. It is known that the number of mast cells is significantly increased in the fibrotic peritoneum. However, the precise mechanism of mast cells in PF is still unknown. Mast cell can be activated by Lipopolysaccharide (LPS). Tumor necrosis factor-α(TNF-α) can be released during mast cell degranulation. It is proved that TNF-α could activate NLRP3/IL-1β pathway, which has been demonstrated to contribute to peritoneal mesothelial cells (PMCs) mesothelial-mesenchymal transition (MMT). In our previous study, Qidan decoction, whose effect is to invigorating qi and activating blood circulation, is proved to ameliorate PF by inhibiting TGF-β. We speculate that Qidan decoction ameliorate PF by acting on NLRP3/IL-1β pathway in PMCs through TNF-α released by peritoneal mast cells. In this study, mast cells activated by LPS will be co-cultured with PMCs, and the Qidan decoction serum will be added to the culture dish. TNF-α, NLRP3/IL-1β, and markers of PMCs MMT will be detected. Meanwhile, intraperitoneal injection of peritoneal dialysis fluids (PDF) on mice will be done to establish PD mice model. Then, mice will be treated with Qidan decoction, mast cell stabilizer, or TNF-α inhibitor. Markers of NLRP3/IL-1β, and PMCs MMT will be detected. This study aims to explore the role of mast cells in PF, and mechanism of Qidan decoction on peritoneal mast cells. We aim to find a new target for the treatment of PF, and above all, to establish and complete the traditional Chinese medicine theory of invigorating qi and activating blood circulation.
肥大细胞参与腹膜纤维化,但具体机制尚不明确。黄芪和丹参广泛应用于临床疾病的治疗,具有抗炎抗氧化等作用,然而其在腹膜纤维化中的功能尚不清除。本研究旨在探索肥大细胞在腹膜纤维化中的作用,并明确芪丹汤通过调节肥大细胞对腹膜纤维化的治疗靶点。我们发现长透析龄组腹膜透析病人腹透液中类胰蛋白酶水平升高,提示肥大细胞参与了腹膜纤维化进程。体外研究表明活化的肥大细胞与腹膜间皮细胞共培养可促进腹膜间皮细胞NLRP3的表达,芪丹汤可以抑制这一过程。采用网络药理学、分子对接及RNA测序,我们发现芪丹汤可能通过MAPK通路抑制肥大细胞活化及腹膜纤维化。体内研究证实,腹膜透析小鼠腹膜肥大细胞活化,类胰蛋白酶释放增加,进一步激活腹膜间皮细胞PAR2/MAPK/NF-κB信号通路介导炎症,并活化TGF-β/Smad通路促进腹膜间皮细胞MMT,伴随VEGF表达上调及细胞连接损伤。芪丹汤可抑制肥大细胞活化、类胰蛋白酶释放及PAR2/MAPK/NF-κB信号通路激活,进而减轻腹膜纤维化。本研究首次证实肥大细胞致腹膜纤维化的具体机制,并明确了芪丹汤通过抑制肥大细胞活化及腹膜间皮细胞PAR2/MAPK/ NF-κB信号治疗腹膜纤维化的靶点,为中医药治疗腹膜纤维化提供新的思路。
国内基金
海外基金